Indivior Pharmaceuticals Inc (INDV) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Indivior Pharmaceuticals Inc   (NASDAQ: INDV)

Select the Financial Report: Select the Period:


Description of Indivior Pharmaceuticals Inc's Business Segments


Indivior Plc is a global pharmaceutical company focused primarily on the treatment of opioid use disorder (OUD) and other substance use disorders. Formerly, a subsidiary of Reckitt Benckiser, Indivior has carved a niche in the development of medications and therapeutic products that address the complexities of addiction and dependence.

Key Segments:

1. Opioid Use Disorder (OUD) Treatment:
This segment is the cornerstone of Indivior’s portfolio, catering to the growing need for effective treatments for OUD, a significant public health crisis in many countries. The company primarily focuses on:

- Medicinal Products:
- Buprenorphine-based Products: The flagship product is Suboxone, a combination of buprenorphine and naloxone, designed to manage opioid dependence. It helps reduce withdrawal symptoms and cravings, aiding patients in their recovery process.
- Sublocade: An extended-release injectable formulation of buprenorphine designed for once-monthly administration. This product offers a convenient option for patients, aiming for improved adherence to treatment regimens.
- Bunavail: A buprenorphine and naloxone film that dissolves in the mouth, providing another method of medication for those recovering from OUD.

2. Substance Use Disorders Beyond Opioids:
While Opioid Use Disorder remains the primary focus, Indivior has been expanding its research and development efforts into other areas related to substance use disorders. This includes potential treatments for:

- Alcohol Use Disorder (AUD): Researching formulations that assist individuals with reduced consumption of alcohol and managing cravings associated with alcohol dependence.
- Stimulant Use Disorders: Exploration of therapies that may aid in the management of dependency on stimulants, thereby expanding the scope of treatment offerings.

3. Digital Health Solutions:
Indivior recognizes the importance of integrating technology with treatment. This includes:

- Patient Support Programs: These programs use digital platforms to provide ongoing support for individuals undergoing treatment. They may include telehealth consultations, educational material, and peer support communities, aiming to bolster the recovery process.
- Mobile Health Applications: Applications that help in tracking medication adherence, provide reminders, and offer resources for coping with cravings have become an important part of Indiviors service offerings.

Services Provided:

1. Patient Support Services:
Indivior provides comprehensive support services aimed at improving treatment adherence and outcomes. These services might include case management, educational resources for patients and their families, and information on accessing treatment facilities.

2. Healthcare Professional Support:
Indivior invests in training programs to educate healthcare providers about OUD treatments and best practices for management. This includes the dissemination of clinical guidelines and the promotion of research findings that underscore the importance of effective treatment protocols.

3. Collaborative Initiatives:
Engaging with governments, non-profit organizations, and other stakeholders, Indivior participates in initiatives aimed at addressing the opioid crisis from multiple fronts. These partnerships often focus on public awareness campaigns, prevention programs, and legislative advocacy to improve access to treatment.

4. Regulatory Affairs and Market Access:
Indivior works to ensure that their products meet the regulatory requirements of various countries. This includes navigating complex health system landscapes to secure reimbursement for their medications, making them accessible to patients who need them.

Research and Development Focus:

R&D is at the heart of Indiviors mission, with substantial investments aimed at innovation in treatment delivery and expansion into new therapeutic areas. The companys research is characterized by:

- Clinical Trials: Engaging in extensive clinical trials to validate the efficacy and safety of new formulations and treatment strategies.
- Novel Delivery Systems: Exploring alternative delivery mechanisms beyond traditional oral medications, such as long-acting injectables and implantable devices for sustained medication release.

Indivior Plc continues to position itself as a leader in addressing the challenges of opioid and substance use disorders, emphasizing the integration of advanced therapeutics and supportive care solutions to promote holistic recovery for patients in need.


Composition of Indivior Pharmaceuticals Inc Revenues by Segments

 
Reportable Segment    100 % of total Revenue
Reportable SUBLOCADE    73.19 % of total Revenue
Reportable US    85.8 % of total Revenue
Reportable US SUBLOCADE    68.77 % of total Revenue
Reportable US Sublingual other    15.77 % of total Revenue
Reportable US PERSERIS    1.58 % of total Revenue
Reportable Rest of World    14.2 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Reportable Segment 317.00 100 %
Reportable SUBLOCADE 232.00 73.19 %
Reportable US 272.00 85.8 %
Reportable US SUBLOCADE 218.00 68.77 %
Reportable US Sublingual other 50.00 15.77 %
Reportable US PERSERIS 5.00 1.58 %
Reportable Rest of World 45.00 14.2 %
Total 317.00 100 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Reportable Segment 19.17 % -
Reportable SUBLOCADE 31.82 % -
Reportable US 22.52 % -
Reportable US SUBLOCADE 33.74 % -
Reportable US Sublingual other -7.41 % -
Reportable US PERSERIS 25 % -
Reportable Rest of World 2.27 % -
Total 19.62 % -74.44 %




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Reportable Segment 277.00 87.38 %
Total 89.00 28.08 %




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Reportable Segment 25.34 % -
Total 89.36 % -57.62 %




Annual Report on Indivior Pharmaceuticals Inc Divisions, Sales by Country

 


Twelve months ended 2025
INDV s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Total 1,240.00 100 %


Twelve months ended 2025
INDV s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total 210.00 16.94 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Reportable Segment - -
Reportable SUBLOCADE - -
Reportable US - -
Reportable US SUBLOCADE - -
Reportable US Sublingual other - -
Reportable US PERSERIS - -
Total 4.38 % 10400 %
OPVEE BARDA - -
US Sublingual other Onerous Contracts - -
Reportable US OPVEE - -
Reportable Most of World - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.